New reimbursement guideline for hepatitis B drug to be drafted

Published: 2012-09-27 06:58:00

Updated: 2012-09-27 06:58:00

The government said Tuesday it will establish a new guideline for the reimbursement of hepatitis B drugs, such as Viread, Hepsera, Baraclude and Zeffix.

Under the guideline, Viread can be reimbursed in patients with HIV-1 infection and chronic hepatitis B and its cocktail therapy is allowed wi...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK